PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers the leading endpoint technology solutions for clinical trials, announces a three-part educational webinar series on oncology trial solutions. Drawing from over 50 years of clinical trial expertise, Clario's webinars will focus on improving the assessment of efficacy, safety and quality of life within oncology clinical trial development programs..

费城，2023年10月31日/PRNewswire/-Clario是一家医疗保健研究技术公司，为临床试验提供领先的终点技术解决方案，宣布一个由三部分组成的肿瘤学试验解决方案教育网络研讨会系列。Clario的网络研讨会将借鉴50多年的临床试验专业知识，专注于改进肿瘤临床试验开发项目中疗效，安全性和生活质量的评估。。

Part one of the series will delve into the current advancements of AI that are enhancing the efficiency of oncology clinical trials with a focus on medical imaging. Additionally, the exciting potential that deep learning and generative AI hold in this dynamic field will be explored.

该系列的第一部分将深入研究AI的当前进展，这些进展正在提高肿瘤学临床试验的效率，重点是医学成像。此外，将探索深度学习和生成AI在这一动态领域所具有的令人兴奋的潜力。

Part two will present research from Clario's eCOA science team, testing accessibility functionality such as zoom-in and zoom-out capabilities in the user interface, assessing the impact of these features on data integrity in both oncology and non-oncology trials.

第二部分将介绍Clario eCOA科学团队的研究，测试用户界面中的放大和缩小功能等可访问性功能，评估这些功能对肿瘤学和非肿瘤学试验中数据完整性的影响。

Part three will focus on assessing safety in oncology development including cardiac safety best practices, adverse event collection using electronic patient-reported outcomes, and early detection of changes in gait and balance through wearable sensor technology.

第三部分将重点评估肿瘤学发展的安全性，包括心脏安全最佳实践，使用电子患者报告结果收集不良事件，以及通过可穿戴传感器技术早期检测步态和平衡的变化。

'We are delighted to introduce Clario's new three-part educational webinar series on oncology trial solutions. With our profound experience, spanning over 5,000 oncology trials and active involvement in securing 175 FDA and EMA approvals for cancer therapies since 2012, we are dedicated to sharing our wealth of expertise and providing our customers with top-tier trial solutions,' remarked Dr.

“我们很高兴介绍Clario关于肿瘤学试验解决方案的新的三部分教育网络研讨会系列。凭借我们丰富的经验，自2012年以来跨越5000多项肿瘤学试验并积极参与确保175项FDA和EMA癌症治疗批准，我们致力于分享我们丰富的专业知识并为客户提供顶级试验解决方案。

Todd Rudo, M.D., Chief Medical Officer at Clario. 'Our series is dedicated to the core facets of efficacy, safety, and quality of life endpoint solutions, offering a tailored approach to meet the dynamic requirements of modern oncology clinical trial development programs.'.

克拉里奥首席医疗官托德·鲁多（Todd Rudo）我们的系列致力于功效，安全性和生活质量终点解决方案的核心方面，提供量身定制的方法来满足现代肿瘤临床试验开发计划的动态要求。

Webinar Dates and Topics:

网络研讨会的日期和主题：

PART 1: Tuesday, November 28, 2023, 11am – 12pm ET: Revolutionizing Oncology Clinical Trials: The Transformative Power and Promise of AI-Enhanced Medical Imaging

第1部分：2023年11月28日星期二上午11点至12点ET：彻底改变肿瘤学临床试验：人工智能增强医学成像的变革力量和前景

PART 2: Monday, December 4, 2023, 11 am – 12 pm ET: Using Scientific Validation to Move the Needle on Accessibility Functionalities

第2部分：2023年12月4日星期一上午11点至下午12点ET：使用科学验证在可访问性功能上移动针头

PART 3: Wednesday, December 13, 2023, 10 am – 11 am ET: Integrating Objectively Measured Safety Endpoints and Patient-Reported Outcomes in Oncology Trials: A Scientific Approach

第三部分：2023年12月13日星期三上午10点至上午11点ET：在肿瘤学试验中整合客观测量的安全性终点和患者报告的结果：一种科学方法

Registration Information:

注册信息：

Registration is now open for the three-part webinar series on oncology trial solutions. Each webinar session will be recorded and available on demand.

现在开放三部分肿瘤学试验解决方案网络研讨会系列。每个网络研讨会会议将被记录并按需提供。

Click here to register for the oncology trial solutions webinar series.

点击这里注册肿瘤试验解决方案网络研讨会系列。

To learn more about the webinars, topics and speakers, please go to Clario.com.

要了解有关网络研讨会，主题和演讲者的更多信息，请访问Clario.com。

About Clario

关于克拉罗

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives.

Clario是一家领先的医疗保健研究和技术公司，为我们的制药，生物技术和医疗器械合作伙伴提供行业中最丰富的临床证据。通过分散，混合和基于现场的试验，我们深入的科学专业知识，全球规模和行业最广泛的终点技术平台使我们的合作伙伴能够改变生活。

Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 30 facilities in nine countries, Clario's global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory approvals for over five million patients in 120 countries.

Clario是唯一结合eCOA，心脏安全，医学成像，精确运动和呼吸终点的技术平台。Clario的全球科学，技术和运营专家团队在9个国家拥有30个设施，帮助为120个国家的500多万患者提供了19000多项试验和870项监管批准。

Our innovation has been transforming clinical trials for 50 years..

我们的创新已经改变了临床试验50年。。

For more information, go to Clario.com or follow us on LinkedIn and Twitter

欲了解更多信息，请访问Clario.com或在LinkedIn和Twitter上关注我们

Clario Media ContactDuncan CantorSr. Director, Corporate Communications[email protected]

Clario Media ContactDuncan CantorSr。公司通讯总监[电子邮件保护]

SOURCE Clario

源Clario